PPARA and metabolic dysfunction-associated steatohepatitis: Lanifibranor’s NATIVE phase 2b trial (24-week data, 2024) yielded broad CMH improvements in MASH patients via pan-PPAR agonism, including 26% TG reduction (AMD −0.5 mmol/L), 0.5% HbA1c lowering, hs-CRP drops (−2.2 mg/L), and DBP decreases (−3.9 mmHg), with adiponectin surges (> 4-fold in 80%) correlating to histological MASH resolution (49%) and fibrosis regression (34%), independent of average 2.5 kg weight gain (128).